Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 10.56
NVIV's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 10.56 )
NVIV' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 10.56

F-Score: 2
Z-Score: -5.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -131.05
NVIV's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -131.05 )
NVIV' s 10-Year ROE (%) Range
Min: -775.86   Max: -360
Current: -131.05

-775.86
-360
ROA (%) -98.22
NVIV's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -98.22 )
NVIV' s 10-Year ROA (%) Range
Min: -590.91   Max: 42.86
Current: -98.22

-590.91
42.86
ROC (Joel Greenblatt) (%) -907.01
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -907.01 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2426.43   Max: -817.6
Current: -907.01

-2426.43
-817.6
EBITDA Growth (%) 32.30
NVIV's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 32.30 )
NVIV' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 306.2
Current: 32.3

0
306.2
EPS Growth (%) 29.40
NVIV's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 29.40 )
NVIV' s 10-Year EPS Growth (%) Range
Min: 0   Max: 306.2
Current: 29.4

0
306.2
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.00
NVIV's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 4.00 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 13.5
Current: 4

0
13.5
EV-to-EBIT -2.93
NVIV's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -2.93 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.93

Current Ratio 2.78
NVIV's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 2.78 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 14.81
Current: 2.78

0.14
14.81
Quick Ratio 2.78
NVIV's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 2.78 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 14.81
Current: 2.78

0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.00
NVIV's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 5.00 )
NVIV' s 10-Year Price/Net Cash Range
Min: 7.94   Max: 38.75
Current: 5

7.94
38.75
Price/Net Current Asset Value 5.00
NVIV's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 5.00 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 7.94   Max: 38.75
Current: 5

7.94
38.75
Price/Tangible Book 4.00
NVIV's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 4.00 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 6.5   Max: 19.38
Current: 4

6.5
19.38
Forward Rate of Return (Yacktman) -17.22
NVIV's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -17.22 )
NVIV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -17.22

Business Description

Industry: »
Compare: » details
InVivo Therapeutics Holdings Corp. is a Nevada Corporation. The Company develops and commercializes technologies for the treatment of spinal cord injuries (SCI). It intends to create a new paradigm of care for SCI. Current treatments consist of a collection of approaches that only focus on symptoms of SCI. To date, it is not aware of any product on the market that addresses the underlying pathology of a SCI. Currently there are no successful spinal cord injury treatment options for SCI patients. InVivo takes a novel approach to SCI and focuses on protection of the spinal cord and prevention of secondary injury rather than regeneration. InVivo's platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The technologies encompass multiple strategies involving biomaterials U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs). InVivo products are biopolymer-based devices that are surgically implanted or injected into the lesion created during traumatic injury, or the 'primary injury'. These scaffolding products protect the damaged spinal cord by mitigating the progression of 'secondary injury' resulting from the body's inflammatory and immune response to injury, and promote neuroplasticity, a process where functional recovery may occur through the rerouting of signaling pathways to the spared healthy issue. Achieving these results is essential to the recovery process, as secondary injury can significantly worsen the immediate damage sustained during trauma. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and humans, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with its research, including infectious disease agents.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against InVivo... Sep 29 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Sep 29 2014
InVivo Therapeutics Announces Appointment of Daniel R. Marshak, PhD to Its Board of Directors Sep 29 2014
EQUITY ALERT: Rosen Law Firm Reminds InVivo Therapeutics Holdings Corp. Investors of Important... Sep 26 2014
UPCOMING DEADLINE: The Law Offices of Vincent Wong Remind Investors of Class Action Involving InVivo... Sep 17 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Sep 17 2014
Shapiro Haber & Urmy LLP Filed the Only Securities Fraud Class Action Lawsuit Brought Against InVivo... Sep 15 2014
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against InVivo... Sep 11 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against InVivo... Sep 10 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Sep 08 2014
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Sep 04 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Sep 02 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Aug 29 2014
InVivo Therapeutics to Present at 2014 Aegis Healthcare Conference Aug 26 2014
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving InVivo... Aug 25 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Aug 25 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in... Aug 23 2014
InVivo Therapeutics to Present at the Stem Cell Meeting on the Mesa Aug 21 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Aug 19 2014
INVESTOR ALERT: Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. Announced by Law... Aug 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK